The Bioshares 2015 : “Long Tail” Awards

Unfortunately, I will not be at Bioshares in New Zealand this weekend to present these well-deserved awards on behalf of the dedicated readers of The Long Tail. However, I have ordered a crate of North Korean Kumdang-2 as the prize for these awards and as soon as it clears AQIS, I will be sure and distribute…

PAA: Congratulations to Roger and the team…

Monumental day! Well done, another bit of doggy data for PharmAust … to follow all the other bits of doggy data we have received this year. Yaaaay! I think for all the world’s cancer patients, Executive Chairman Dr. Roger Aston’s comments bode particularly well, especially for women : Combining chemotherapy with PPL-1 in a target species with…

Clinical Trial Communication Matters

Over the past few months I have poked several companies in the eye for the appalling quality of their clinical communication. I have specifically paid attention to Novogen (ASX : NRT), Benitec (ASX : BLT), Regeneus (ASX : RGS) and a few others. It is my position is that there is a consistently low quality and sensationalist ethos…

NRT, ANP, PYC, ACL, OBJ : A Week in Contrast

Last week was a pretty exciting week in Australian life sciences. Quite a bit happened, in fact I struggled to stay on top of it while being on vacation. We’ve seen a couple of good things happen, like PharmAxis, Sirtex recovery, etc. that are real bright spots on the Aussie biotech landscape. We’ve seen some…

The Shock Jock : Market Roundup

You give me a royal pain in the ass, if you want to know the truth. – Holden (J.D. Salinger) When I announced earlier in the week that I would no longer be commenting on HotCopper, I thought that would be the end of the annoying, low-intelligence comments mostly aimed at some degree of personal…

PharmAust Dog#2. Yay.

Gimme a break… Seriously. WTF. When I wrote about PharmAust (ASX:PAA) two weeks ago, I flippantly asked whether the company was going to give a mutt-by-mutt breakdown of their veterinary study of PPL-1. It really pisses me off when companies abuse the continuous disclosure rules to create market hype. It pisses me off even worse…

PharmAust : Every dog has its day

I’m going to take a different tack with this post. If I am honest with you, the last couple of posts left me feeling vacant and dissatisfied. Plus I received about 50 abusive notes from MediBio shareholders suggesting that I had missed the whole point (quite possible) and that I should focus on writing children’s…